https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 The clinical profile of NMOSD in Australia and New Zealand https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42666 Wed 31 Aug 2022 14:05:33 AEST ]]> Locus for severity implicates CNS resilience in progression of multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52436 Wed 11 Oct 2023 14:54:40 AEDT ]]> Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46138 Tue 04 Apr 2023 18:59:19 AEST ]]> Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> Response to treatment in NMOSD: the Australasian experience https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46199 Mon 14 Nov 2022 11:22:52 AEDT ]]> Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42294 Fri 19 Aug 2022 14:58:38 AEST ]]>